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Abstract
Background and Objectives Fexinidazole is a 5-nitroim-
idazole recently included in a clinical efficacy trial as an
oral drug for the treatment of human African trypanoso-
miasis (HAT). Preclinical studies showed it acts as a
pharmacologically active pro-drug with two key active
metabolites: sulfoxide and sulfone (the most active metab-
olite). The present studies aimed to determine the best dose
regimen for the treatment of stage 2 sleeping sickness
patients, which could eventually also treat stage 1 patients.
Methods Fexinidazole was assessed in 154 healthy adult
male subjects of sub-Saharan African origin. Three initial
first-in-human studies and two additional studies assessed a
single ascending dose and multiple ascending doses (both
under fasted conditions), tablet versus suspension formu-
lation and food effect (fasted vs. high-fat meal and field-
adapted food), and multiple ascending doses with a loading
dose regimen under fed conditions.
Results Fexinidazole was well-tolerated in a single dose
from 100 to 3,600 mg, with quick absorption of the parent
drug and rapid metabolism into sulfoxide [time to maxi-
mum concentration (tmax) 2–5 h] and sulfone (tmax
18–24 h). The tablet formulation was approximately 25 %
less bioavailable than the suspension, and food intake
increased drug absorption and plasma concentrations of
fexinidazole and its two metabolites by approximately
200 %. Fourteen-day multiple ascending dosing adminis-
tered up to 3,600 mg/day in fasted conditions showed that
fexinidazole was generally well-tolerated (mild to moder-
ate, spontaneously reversible drug-related adverse events).
Following the high-fat food effect finding, another study
was conducted to evaluate the impact of a low-fat regimen
closer to that of the target population, showing that the type
of meal does not influence fexinidazole absorption. The last
study showed that a loading dose of 1,800 mg/day for
4 days followed by a 1,200 mg/day regimen for 6 days
with a normal meal provided the desired exposure of fex-
inidazole and its metabolites, particularly sulfone, with
good tolerability. Based on preclinical evidence from a
chronic infection mouse model, systemic drug concentra-
tions obtained are expected to be clinically effective in
stage 2 HAT.
Conclusions These studies show that fexinidazole can be
safely assessed in patients as a potential oral cure for both
stages of HAT.
1 Introduction
Human African trypanosomiasis (HAT) is transmitted
through the bite of tse-tse flies infected with either Try-
panosoma brucei gambiense (in west and central Africa) or
Trypanosoma brucei rhodesiense (in eastern and southern
The studies were registered with ClinicalTrials.gov under the
following numbers: NCT00982904, NCT01340157 and
NCT0148370.
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Africa), causing chronic or acute sleeping sickness,
respectively [1, 2]. Both forms of the disease occur in two
stages, the first of which is characterised by non-specific
symptoms, such as fever, headache, malaise and peripheral
oedema. The second stage, which occurs once the parasite
has crossed the blood–brain barrier, includes severe neu-
rological symptoms, such as sleeping disturbances,
behavioural changes and convulsions that, without treat-
ment, progress to coma and eventually death.
Coordinated efforts to control the disease have resulted
in a sustained decrease in the number of cases over the last
10 years, down to 10,000 new cases in 2010. Sub-Saharan
Africa remains the worst affected area, with approximately
7,000 new cases reported in 2012, and approximately
69 million people are at risk of contracting HAT, the
majority from T.b. gambiense infection (57 million).
Therefore, much needs to be done if the WHO goal of
global HAT elimination by 2020 is to be achieved [3, 4].
Current treatment for stage 2 HAT relies on toxic and
difficult to use drugs. For example, melarsoprol treatment
is highly toxic with up to 9 % drug-induced mortality in
patients treated with the drug due to reactive encephalop-
athies [5]. Eflornithine treatment is expensive and logisti-
cally difficult in rural clinics as it requires four daily
intravenous infusions over 14 days [6]. Despite being a
clear improvement on other alternatives, the recently
implemented combination of a simple regimen of intrave-
nous eflornithine and oral nifurtimox [nifurtimox–eflorni-
thine combination treatment (NECT)] [7, 8] remains far
from ideal, as it still requires slow intravenous drug
administration (14 infusions over 7 days), a procedure that
can only be performed by well-trained staff in a hospital
setting. The populations at risk of sleeping sickness are
most often economically disadvantaged, living in rural
communities far away from treatment centres and would
therefore greatly benefit from a safe, easy-to-use, oral
treatment.
Fexinidazole was recently developed as a novel drug
candidate for HAT through a screening of over 700 nitro-
heterocyclic molecules against T. brucei [9]. Fexinidazole
is a 2-substituted 5-nitroimidazole that exhibits in vitro and
in vivo activity against both T.b. rhodesiense and T.b.
gambiense [9, 10]. Oral administration of fexinidazole
cures mouse models of both acute and chronic HAT
infection, and pre-clinical absorption, distribution, metab-
olism and elimination studies show that it is well-absorbed
and readily distributes throughout the body, including the
brain [9]. Whilst fexinidazole, like many nitroheterocycles,
is mutagenic in the Ames test, it is not genetically toxic to
mammalian cells in vitro or in vivo and is therefore not
expected to pose a genotoxic risk for humans [9, 11]. In all
investigated animal species, fexinidazole was rapidly me-
tabolised through oxidation, resulting in the formation of at
least two pharmacologically active metabolites, fexinidaz-
ole sulfoxide (M1) and fexinidazole sulfone (M2), which
are presumed to account for much of the trypanocidal
activity in animal models [9]. No formal studies have been
carried out to determine the mode of action of fexinidazole,
but it is likely that the compound acts in a similar fashion
to other 5-nitroimidazole drugs, which have a negative
redox potential [12–14]. In order to investigate safety,
tolerability and pharmacokinetics of fexinidazole, and
establish a phase II dosing regimen to be assessed in
patients with second stage sleeping sickness, we conducted
a series of five studies in which healthy human subjects
received single ascending doses (SAD), single fixed doses
or multiple ascending doses (MAD) of orally administered
fexinidazole according to different dosing regimens; we
also investigated the relative bioavailability of different
oral formulations, and the impact on bioavailability of
different types of food.
2 Methods
The study protocols were approved by an independent
ethics committee (CPP Ile de France III, Paris, France) and
by the French health authorities (AFSSAPS; the French
Agency for the Safety of Health Products) prior to the start
of each study and written informed consent was obtained
from all participants. The studies were conducted in
accordance with the ethical principles stated in the Dec-
laration of Helsinki (as revised by the 59th World Medical
Association General Assembly in Seoul, Korea, October
2008), French Huriet law (No. 2004-806), and the Good
Clinical Practice guidelines [15] and standard operating
procedures for clinical investigation and documentation in
force at the study site.
Details of study design and analytical methods
employed are provided in the Electronic Supplementary
Material.
2.1 Participants
Eligible subjects were healthy male volunteers, French
residents of sub-Saharan origin, 18–45 years of age, with
both parents of sub-Saharan African origin and a body
mass index of 18–28 kg/m2 at the time of screening. Any
subject with evidence of clinically significant acute or
chronic disease, including known or suspected HIV, hep-
atitis B or C virus infection, who had previously received
fexinidazole, or who had a positive drug screening test was
excluded from the studies. Liver enzymes [aspartate ami-
notransferase (AST), alanine aminotransferase (ALT) and
alkaline phosphatase] were required to be within normal
ranges.
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2.2 Procedures
The first protocol was a combined, three-part under fasting
conditions, sequential first-in-human study designed to
obtain safety, tolerability and pharmacokinetic data after
single and multiple oral administration of ascending doses
of fexinidazole. The study was divided into three succes-
sive parts. Study 1A was a double-blind placebo-controlled
SAD study. Study 1B was an open-label, crossover com-
parative bioavailability study of tablet versus suspension,
and food effect with tablet—tablet/fasted versus tablet/
high-fat rich meal. Study 1C was a double-blind placebo-
controlled MAD study. The tablet was used in all consec-
utive studies. Following completion of these studies, two
additional studies were carried out, the first to assess the
impact of different types of food (Plumpy’Nut and rice
and beans) on the relative bioavailability of fexinidazole
(Study 2); the final study was a double-blind placebo-
controlled study under fed conditions (Study 3) to select
one of the two optimised multiple dosing schedules to be
used in subsequent clinical trials in patients based on
modelling of pharmacokinetic data.
2.3 Dosage and Formulation Justification
The starting dose in the initial SAD study was defined on the
basis of the 200 mg/kg/day no observed adverse effect level
dose determined in 4-week toxicity studies in the fasted rat
and dog [9] and, considering the lowest of these human
equivalent doses and a safety margin of 1:20, a starting dose
of 1.6 mg/kg was calculated with an initial single dose of
100 mg for both the suspension and tablet forms.
2.4 Study Drugs
Fexinidazole (1H-imidazole, 1-methyl-2-[[4-(methylthio)
phenoxy] methyl] 5-nitro-imidazole) is insensitive to light,
air, oxygen and moisture and is stable under accelerated
storage conditions of 40 C/75 % relative humidity for at
least 6 months and for at least 24 months at 25 C/60 %
relative humidity.
The drug products used in the present studies consisted
of two forms with matching placebo:
• A powder-in-bottle (PIB) formulation consisting of
100, 200 or 600 mg micronised fexinidazole powder or
matching placebo reconstituted in an aqueous solution
as an oral suspension.
• A tablet form consisting of 200 or 600 mg tablets of the
investigational product with matching placebo. The
600 mg dosage form was selected for further clinical
studies and potential commercialisation. Fexinidazole
tablets have an estimated shelf-life of 24 months.
2.5 Design of Studies
Full details of the study designs are provided in the Elec-
tronic Supplementary Material.
A safety review committee (SRC) was constituted to
oversee ascending-dose studies to allow dose progression;
it consisted, at minimum, of the investigator or deputy and
at least one sponsor representative. Additional SRC
members were appointed or called in ad hoc, as required,
including a statistician, pharmacokinetics experts and an
independent third-party representative. In all studies, seri-
ous adverse events (SAEs) were defined as per the Good
Clinical Practice guideline [15].
2.5.1 Study Protocol 1 (NCT00982904)
Study protocol 1 was a combined protocol that included
three parts (study 1A–C).
Study 1A was a double-blind, within-cohort placebo-
controlled SAD study of ascending doses of fexinidazole
ranging from 100 to 3,600 mg in the form of an oral sus-
pension of the PIB formulation carried out in cohorts of
eight subjects (six active and two placebo) to determine
safety and tolerability of the drug [16]. For each dose,
adverse events (AEs), electrocardiogram (ECG) findings,
vital signs and clinical laboratory tests (haematology, blood
chemistry and urinalysis) were assessed for up to 48 h post-
dose in a blinded fashion by the SRC before administration
of the next dose. Blood samples for drug assay and plasma
pharmacokinetic analysis were drawn until discharge.
Urine was also collected for pharmacokinetic analysis.
A randomised, open-label, three-way crossover phar-
macokinetic study (Study 1B) was carried out to assess the
effect of single-dose fexinidazole, either as a suspension
(PIB formulation) under fasted conditions (x) or as tablets
under fasted (y) or fed conditions (z) on the bioavailability
and safety of the study drug. Food consisted of a standard
high-fat content meal. Twelve subjects were randomised;
each subject received one of the three treatments (x, y or
z) on three occasions in an open, randomised crossover
design separated by a 14-day washout. The administered
dose of 1,200 mg corresponded to a third of the maximum
dose administered in study 1A. Determination of the free
fraction of fexinidazole and its two metabolites was
included in this study.
A randomised, double-blind, within-cohort, placebo-
controlled MAD study evaluated fexinidazole 1,200, 2,400
and 3,600 mg doses (tablet formulation) as a single daily
dose in three cohorts of eight subjects (six active and two
placebo) for 14 days under fasting conditions (Study 1C).
For each dose level, standard safety and tolerability mea-
surements were regularly performed (AEs, ECG record-
ings, vital signs and biochemical analyses: haematology,
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biochemistry, enzymology and haemostasis) up to 48 h
after the last dose on day 14 and were assessed in a blinded
fashion by the SRC. Moreover, 24-h 12-lead Holter ECG
was recorded before dosing and on day 14.
2.5.2 Study Protocol 2 (NCT01340157)
Study protocol 2 was a food interaction study performed to
evaluate, in addition to the previous high-fat rich meal (Study
1B), the effect on fexinidazole bioavailability of two dif-
ferent meals, more representative of the local diet in target
regions: a field-adapted meal of rice and beans, an easily
quantifiable and non-fat carbohydrate food; and a field-
available high-fat meal (Plumpy’Nut). The design was a
randomised, open-label, three-way crossover study to assess
the effect of the two different types of food versus fasted
conditions on the bioavailability and safety of a single
1,200 mg dose (two tablets of 600 mg). At each treatment
sequence (treatment x = fasted, treatment y = Plumpy’-
Nut, and treatment z = rice and beans) safety and tolera-
bility follow-up were done up to 48 h post-dose, and an end-
of-study visit was performed on day 8 of the last period of
treatment before final discharge. Subjects participated in
each of the three food regimens in a randomised order sep-
arated by a wash-out period of at least 14 days between
doses, based on the available pharmacokinetic data from
Study 1A, in order to prevent any carryover effects. In
addition, blood samples for drug assay and pharmacokinetic
analysis were taken until day 8 post each dosing.
2.5.3 Study Protocol 3 (NCT0148370)
Study protocol 3 was carried out following a population
pharmacokinetic evaluation using all available data from
the preceding studies exploring the various dosing regi-
mens with food. The aim was to ascertain the most efficient
dosing schedule in terms of rapidity to peak steady state
and extended duration of systemic bioavailability of the
fexinidazole sulfone metabolite M2. Simulations of the
cerebrospinal fluid concentration were included using the
free fraction determined in plasma in Study 1B. The target
was to obtain the same plasma concentration that provided
a curative effect in the GVR35 chronic mouse model [9,
10]. This murine model is, to date, the most widely studied
laboratory model of the chronic disease, and fexinidazole
cured the disease in this model, with oral dosing resulting
in plasma drug concentrations of the sulfone metabolite of
[10,000 ng/mL for a number of hours post-dosing.
The design was a randomised, double-blind, placebo-con-
trolled MAD study performed in two cohorts of 16 subjects (12
active and six placebo) to evaluate two dosing regimens
determined through pharmacokinetic modelling and simulation
analysis. For each dose level, standard safety and tolerability
(AEs, ECG findings, vital signs and clinical laboratory test
results) up to 48 h after the last dose on day 10 were assessed in
a blinded fashion by the SRC. Moreover, 24-h 12-lead Holter
ECG was recorded before dosing and on days 4, 7 and 10 after
dosing. Blood samples for drug assay and pharmacokinetic
analysis were drawn until the end of study visit.
The following dosing regimens were studied
sequentially:
Cohort 1: fexinidazole 1,800 mg or placebo from day 1
to day 4, then fexinidazole 1,200 mg or placebo from day 5
to day 10.
Cohort 2: fexinidazole 2,400 mg or placebo from day 1
to day 4, then fexinidazole 1,200 mg or placebo from day 5
to day 10.
2.6 Bioanalytical Assay
Fexinidazole and its sulfoxide (M1) and sulfone (M2)
metabolites were analysed on a Supelco Ascentis Express
C18, 2.7 lm, 50 9 4.6 mm I.D. column using a validated
liquid chromatography–tandem mass spectrometry (LC-
MS/MS) method. In lithium heparinised plasma, the
quantification limit of fexinidazole, M1 and M2 was 0.5, 10
and 10 ng/mL, respectively (see the Electronic Supple-
mentary Material for further details).
2.7 Pharmacokinetic Analysis
Pharmacokinetic parameters for fexinidazole and its sulf-
oxide (M1) and sulfone (M2) metabolites were estimated
using non-compartmental methods (WinNonlin software,
version 5.2, Pharsight Corporation, Mountain View, CA,
USA). The pharmacokinetic parameters studied were
maximum plasma concentration (Cmax), time to reach Cmax
(tmax), elimination rate constant (ke), area under the plasma
concentration–time curve (AUC) from time zero to the last
measurable concentration (AUClast) and, when applicable,
AUC from time zero to 24 h post-dose and from time zero
to infinity (AUC24 and AUC?) determined by a linear
trapezoidal method, terminal elimination half-life (tb)
determined by linear regression using at least three time
points, apparent total clearance of the drug from plasma
(CL) after oral administration (CL/F) estimated using the
ratio of dose to AUC, apparent volume of distribution after
oral administration (Vd/F) determined as CL/ke. Renal
clearance of the drug from plasma (CLR) was estimated
using the ratio of the amount of unchanged drug excreted
into urine to the AUC for the time period considered.
2.8 Statistical Analysis
In Studies 1A and 1C, dose proportionality of fexinidazole
was assessed based on plasma pharmacokinetic parameters
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over the complete dose range at each day of complete
pharmacokinetic assessment using the power model of
Gough et al. [17]. Cmax or AUCs and the dose value were
log-transformed and evaluated using a linear mixed-effect
model including a fixed effect due to log (dose) and a
random effect due to subject. The dose proportionality was
confirmed if the 90 % confidence interval (CI) (bl, bu) of
the mean slope b was contained completely within the
following critical region:
1 þ logð0:8Þ




where r, defined as the dose ratio, is equal to h/l, h being
the highest dose and l the lowest dose.
In Studies 1B and 2, analyses of Cmax and AUC for food
and formulation effects were carried out by analysis of var-
iance using PROC MIXED on the logarithmically trans-
formed data including fixed factors for treatment, period and
sequence. A random effect for the subject nested within the
sequence was included in the model. The 90 % standard CI
limits for relative treatment differences were calculated by
geometric means based on logarithmic transformation of the
intra-individual ratios of Cmax and AUC.
3 Results
3.1 Safety and Tolerability
Summary demographic data for all study subjects are
shown in Table 1.
3.1.1 Study Protocol 1
3.1.1.1 Study 1A In Study 1A, a total of 72 subjects were
dosed, and all completed the study without relevant pro-
tocol deviations. Fifty-four subjects received the active
drug. A total of eight mild AEs were reported, only three of
which were considered to be possibly related to fexini-
dazole administration, the most frequent being headache.
Two headaches were considered as probably related, and
one case of pruritus was considered as unlikely to be
related. No subjects were discontinued from the study due
to AEs; no subject had SAEs. Neither trends nor relevant
changes from baseline were observed in vital signs, ECG
parameters, physical examination, or in any laboratory
parameters assessed. The maximum tolerated dose was not
reached and the highest administered dose, defined as the
maximum administered dose, was 3,600 mg.
3.1.1.2 Study 1B Further to replacement of one subject
who withdrew consent for personal reasons, a total of 13
subjects were dosed in Study 1B with fexinidazole
1,200 mg, either as a suspension under fasted conditions
(x) or as tablets under fasted (y) or fed conditions (z).
Twelve subjects completed the study without any relevant
protocol deviation. Eleven AEs were reported, none of which
were serious according to the definitions given by Interna-
tional Conference on Harmonisation (ICH) guidelines [18].
Six were considered possibly related to fexinidazole (five
mild and one moderate), the most frequent being headache.
Neither trends nor relevant changes from baseline were
observed in vital signs, ECG parameters, physical exami-
nation, or in any laboratory parameters assessed.
3.1.1.3 Study 1C In Study 1C, 27 subjects were given
ascending doses of fexinidazole/placebo tablets, 17 of
whom received active drug for 14 days, and nine received
placebo for 14 days. One received treatment for 7 days only
(the last subject in the study). It was decided to interrupt the
treatment early after an SAE (before blind break) was
reported for another subject—it was subsequently discov-
ered that the subject had actually received placebo. Of the
27 subjects, 15 experienced at least one AE. All AEs
recovered spontaneously or following single episodic
symptomatic treatment. The most frequent AE was head-
ache, with a total of 17 episodes reported by 11 subjects.
Two SAEs were reported by subjects who received
fexinidazole: one subject (2,400 mg) asked to stop the
study after 9 days of treatment due to intermittent head-
ache, anxiety, vomiting, liquid stool episodes and myalgia
of inferior limbs. Moderate anxiety had started the day
preceding the first study drug administration and appeared
to be the only cause of hospitalisation. The other SAE, on
day 15, was observed in a second subject (3,600 mg) who
exhibited a marked elevation in AST (10 times the normal
upper limit) and ALT (7.4 times the normal upper limit).
The volunteer was kept in the unit for surveillance for 48 h
as the decrease was as strong as the increase. The subject
was followed up for an additional 15 days until transami-
nase values were back to normal. Bilirubinaemia remained
normal throughout the follow-up period.
Other laboratory abnormalities were observed in sub-
jects under active treatment. Most of these were considered
to be incidental and not clinically relevant, but it was also
noted that, whilst remaining within normal ranges, creati-
nine levels increased progressively from the fourth day of
treatment to its end, and returned to baseline values
thereafter. This increase was not dose related and no other
renal parameters were found to be similarly increased.
Variations in creatinine were considered likely to be related
to the drug class [19]. In addition, transaminase levels
increased above normal upper limits, generally after
treatment completion, regardless of the dose, even though
the extent of the increase appeared to be dose related.
Neither trends nor relevant changes from baseline were
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observed in vital signs and physical examination. Changes
in ECG parameters consisting of an increase of heart rate
and prolongation of the QT interval (within normal range)
were observed across several dose levels, with no clear
dose effect seen. These changes were of limited magnitude
and generally remained strictly within normal ranges. None
of the changes were considered to be of clinical relevance.
3.1.2 Study Protocol 2
Among the 12 subjects in Study 2 receiving fexinidazole
1,200 mg as oral tablets under fasted conditions or with
one of the two meals, one withdrew consent and was not
replaced. A total of nine AEs were reported, none of which
was serious. Seven of the reported AEs were considered to
be possibly related to fexinidazole administration (one
under fasted conditions, one with concomitant Plumpy’-
Nut intake, and five with concomitant rice and beans
consumption). The intensity of AEs were mild (n = 5) or
moderate (n = 2). The most frequent AE reported was
headache (four cases reported by three subjects). No sub-
jects were discontinued from the study due to AEs. Neither
trends nor relevant changes from baseline were observed in
vital signs, ECG parameters, physical examination, or in
any laboratory parameters assessed.
3.1.3 Study Protocol 3
Thirty subjects were randomised in Study 3. In the first
cohort of nine subjects receiving fexinidazole
1,800 ? 1,200 mg as oral tablets, five subjects withdrew
consent during the course of the study due to digestive
disorders (nausea and vomiting). As a cohort effect was
suspected, all were replaced and dosed in subgroups of
three subjects per group. Using this dosing schedule, all
subjects completed the dosing regimen. In the second
cohort receiving fexinidazole 2,400 ? 1,200 mg as oral
tablets, two subjects withdrew due to AEs and were not
replaced. This second dosing regimen was stopped after the
inclusion of six subjects into the cohort. Overall, 22 of the
30 included subjects completed the study (18/24 in the first
cohort and 4/6 in the second cohort). A total of 98 AEs
were reported, of which only three were not considered to
be related to the study drug (nasopharyngitis, and one
episode of dizziness and headache; see details in Table 3).
The incidence of AEs was higher within the first days
following treatment initiation (loading dose). Of the AEs
with a possible relationship to the study drug (83 %), the
most frequent were gastrointestinal and nervous system
disorders. Gastrointestinal disorders consisted mainly in
vomiting (23/50), while central nervous system disorders
were essentially headache (27/32). Vomiting episodes
generally occurred up to 6–9 h post-dose. Given that the
tmax of fexinidazole is 2–4 h, the drug has long been
absorbed by the time vomiting starts, suggesting that it is
due to central effects. Two subjects in the second cohort
experienced sustained anxiety with isolated episodes of
panic attacks on the fifth day of dosing, which disappeared
over the following 2–3 days after cessation of study drug
treatment.
Mean haematology parameters remained within normal
ranges throughout the study duration and, whilst sporadic
individual abnormalities were observed, none was consid-
ered of clinical relevance. Mean biochemistry parameters
Table 1 Demographic
characteristics of subjects in
Studies 1–3
BMI body mass index, SD
standard deviation
Parameter Single-dose studies Multiple-dose studies
Study 1A Study 1B Study 2 Study 1C Study 3
Age (years)
N 72 13 12 27 30
Mean (SD) 27.0 (5.9) 27.4 (6.6) 28.1 (7.8) 27.8 (4.9) 28.5 (6.2)
Range 19–45 19–43 19–44 18–40 19–40
Bodyweight (kg)
N 72 13 12 27 30
Mean (SD) 75.86 (10.83) 71.57 (5.20) 75.33 (9.43) 74.80 (9.72) 75.00 (9.24)
Range 53.2–99.9 64.5–81.3 58.5–87.5 55.2–96.0 61.2–93.2
Height (cm)
N 72 13 12 27 30
Mean (SD) 179.2 (6.4) 174.4 (6.3) 180.2 (6.9) 178.7 (5.7) 177.9 (7.7)
Range 163–193 165–184 173–198 163–187 162–196
BMI (kg/m2)
N 72 13 12 27 30
Mean (SD) 23.57 (2.57) 23.56 (1.59) 23.24 (3.09) 23.43 (2.85) 23.73 (2.73)
Range 18.0–28.5 21.3–26.9 19.1–27.1 18.8–28.2 18.2–28.4
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also remained within normal limits, except for creatinine
and creatine phosphokinase (CPK). Creatinine elevations
had also been observed in Study 1C and, as no other
abnormalities in renal parameters were observed, they were
considered likely to be related to the drug class [19]. It is
also possible that the observed CPK increases were related
to physical exertion; the abnormal values were not con-
sidered clinically relevant. A total of ten post-dose eleva-
tions of liver function parameters were observed in both
cohorts. Mean bilirubin (conjugated, free and total) values
were comparable between the placebo and the two active
dose groups, with no major trend in changes from baseline.
Most of these were limited, and none of these abnormali-
ties in laboratory data were considered to be of clinical
relevance.
No abnormalities or out of range values were detected in
the safety ECG analyses. Only one Holter-extracted ECG
out of more than 4,000 revealed an increase from baseline
of 60 ms, but remained within the normal ranges. The 24 h
Holter recordings were analysed using an analytical
method similar to that of Malik et al. [20] using five rep-
licates per time point; double delta from baseline for cor-
rected QT (QTc) interval and individual corrections based
on QT/RR pattern at D-1.
As the regimen to be implemented in the planned pivotal
efficacy study had been completed (cohort 1), and due to
the poor tolerability observed in subjects in the second
cohort, it was decided not to expose more subjects to this
second dosage regimen and to stop the study.
A summary of AEs is provided in Tables 2 (single dose)
and 3 (multiple-dose studies).
3.2 Pharmacokinetics
3.2.1 Pharmacokinetics of Fexinidazole and its
Metabolites Fexinidazole Sulfoxide (M1)
and Fexinidazole Sulfone (M2)
The pharmacokinetics of fexinidazole and its principle
metabolites are summarised in Tables 4, 5, 6, 7 and 8.
Examples of mean fexinidazole, M1 and M2 plasma con-
centrations versus time profiles under different conditions
of administration are illustrated in Figs. 1 and 2. Overall,
the profile of plasma concentrations of fexinidazole and its
two principle metabolites is similar to that seen in labo-
ratory animals [9, 12, 14].
3.2.2 Single-Dose Pharmacokinetics of Fexinidazole
(Study 1A, Study 1B and Study 2)
After administration of single doses of fexinidazole in
fasted conditions, the drug was rapidly absorbed (median
tmax between 3 and 4 h post-dose). Thereafter, plasma
concentrations exhibited a multiphasic decline, with a
comparable elimination (geometric mean tb) for all dose
levels of between 9 and 15 h. The primary metabolite, M1,
exhibited a pharmacokinetic profile more consistent with
the parent drug, since the Cmax as well as the terminal
plasma tb occurred rapidly and in a similar range (median
tmax between 2 and 5 h post-dose and a geometric mean t
at around 8–15 h). Fexinidazole sulfone (M2) was found to
be the major metabolite following oral administration of
fexinidazole. Its plasma concentrations increased more
slowly than the parent compound (or M1), reaching a
maximum with a median time between 18 and 24 h post-
dose, following which plasma concentrations decreased
progressively with a geometric mean tb of about 18–25 h
(Fig. 1). Inter-individual variability of Cmax and AUCs
were slightly higher for the parent compound than for the
metabolites and ranged between 19 and 77 % for fexini-
dazole, 8 and 59 % for M1, and 14 and 55 % for M2.
Summary data are shown in Tables 4, 5 and 6.
Between 0.75 and 3.15 % of the fexinidazole dose was
recovered in urine over the 168 h measured (sum of
unchanged and transformed drug), after oral administration
of ascending single doses, indicating that the elimination
route of fexinidazole is almost entirely extra-renal. The
corresponding renal clearance ranged from 1.23 to
6.01 mL/h.
The rate and extent of absorption of fexinidazole was
less than dose proportional over the studied dose range
(100–3,600 mg). When the administered dose was
increased twofold, Cmax and AUC? increased 1.46- and
1.65-fold, respectively. The same held true for the metab-
olites, as a doubling of the dose resulted in an increase in
Cmax and AUC? by 1.33- and 1.65-fold for M1 and 1.47
and 1.55-fold for M2, respectively. The observed dose
proportionality of Cmax and AUC? is illustrated in Fig. 2
for fexinidazole and the M2 metabolite.
Comparison of the tablet formulation and the oral sus-
pension (fexinidazole 1,200 mg dose: Study 1B) showed
that the dissolution and distribution profiles of fexinidazole
were very comparable, but that there was a decrease of
about 25 % of the relative bioavailability of the tablet
form.
Unexpectedly, when fexinidazole 1,200 mg tablets were
administered with a high-fat breakfast (Study 1B), the
relative bioavailability of the drug compared with fasted
conditions showed a threefold increase for both rate and
extent of absorption, as expressed by Cmax and AUC?
(Table 4; Fig. 3). In parallel, the levels of M1 and M2
increased proportionally.
Comparable results were obtained when fexinidazole
was taken with either a high-fat (Plumpy’Nut) meal or a
non-fat meal of rice and beans likely to be available to
HAT patients in the field (Study 2), as summarised in
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Table 4. These results were unexpected and could not be
predicted on the basis of known data with other drugs of
the same class [21, 22]. Overall, concomitant food intake,
such as Plumpy’Nut or rice and beans, induced a marked
increase of the relative bioavailability of fexinidazole: 2.8-
and 1.6-fold increase for Cmax and AUC?, respectively,
with Plumpy’Nut and 2.9- and 2-fold increase for Cmax
and AUC? with rice and beans. The concentrations of M1
and M2 increased proportionally. In addition, systemic
concentrations of fexinidazole and both metabolites were
increased to a slightly higher extent after dosing with the
rice and beans meal than with Plumpy’Nut; on average,
by ?20, ?19, ?16 % (based on AUCs) for fexinidazole,
M1 and M2, respectively. The metabolic ratios (metabolite
vs. fexinidazole) of Cmax and AUCs were comparable
between the three treatments, although there was a slight
reduction under both fed conditions. This decrease seemed
to be limited, suggesting that the increase of relative bio-
availability induced by the concomitant food intake did not
lead to significant changes in the rate of biotransformation
of fexinidazole to M1, or of M1 into M2.
Protein binding was estimated from the ratio of the free
fraction concentration over the corresponding total con-
centration measured, and appeared to be constant across
time with the free fractions accounting for about 2 % for
fexinidazole, 59 % for M1 and 43 % for M2, reflecting the
known in vitro data [10].
3.2.3 Multiple-Dose Pharmacokinetics of Fexinidazole
(Study 1C and Study 3)
After multiple oral administrations of fexinidazole tablets
with doses ranging from 1,200 to 3,600 mg for 14 days,
steady-state plasma drug concentrations were reached
between 5 and 7 days for fexinidazole and M1, and
between days 9 and 10 for M2. Overall, pharmacokinetic
parameters remained unchanged when compared to single-
dose studies. The rate and extent of absorption of fexini-
dazole and both metabolites were markedly less than dose
proportional over the studied dose range since, after a
14-day administration, mean Cmax and AUClast increased
by 1.17 and 1.34, respectively, when the dose doubled and
by 1.50 and 1.61, respectively, for a threefold increase in
dose. The same held true for the metabolites, as the mean
Cmax and AUClast of M1 increased by 1.72 and 1.86 when
the dose increased from 1,200 to 3,600 mg, while the mean
Cmax and AUClast of M2 increased by 2.08 and 2.005.
Summary data are shown in Table 7.
Based on the area over the dosing interval AUClast data
there was an accumulation on day 7 compared with day 1 of
1.5, 2.1 and 7.3 for fexinidazole, M1 and M2, respectively.
On day 14 the accumulation was comparable with day 7.
As reported with single-dose administration, urinary
elimination of fexinidazole, M1 and M2 was negligible.
The effect of a loading dose and concomitant food
intake following multiple dosing were assessed in Study 3.
In terms of the simulated concentrations that could be
expected, the median M2 Cmax of the highest regimen was
predicted to be around 35,000 ng/mL and the median
maximum AUC to be around 793,000 ngh/mL compared
with the plasma concentration observed in healthy volun-
teers after administration of 3,600 mg for 14 days, which
was close to the maximum AUC observed (603,000 ngh/
mL) at maximum dose of Study 1C. As the dose was well-
tolerated, the SRC authorised continuation to the second
dose regimen of 2,400 mg, followed by 1,200 mg. The
study shows that the dosage regimen used for cohort 1
yields high M2 concentrations, with plasma concentrations
Table 2 Number (%) of subjects experiencing study drug-related adverse events and number of adverse events after single oral doses of
fexinidazole (Studies 1A, 1B and 2)
AE Fasted conditions (Studies 1A, 1B and 2) Fed conditions
Study 1B Study 2b
100 mg 200 mg 1,200 mg 2,400 mg 3,000 mg 3,600 mg 1,200 mg 1,200 mg
Number of subjects exposed 6 6 41a 6 6 6 12 23
Headache 1 (17) [1] 3 (7) [3] 1 (17) [1] 2 (17) [2] 3 (13) [3]
Vomiting 1 (4) [1]
Nausea 1 (4) [1]
Diarrhoea 1 (8) [1] 1 (4) [1]
Abdominal pain 1 (2) [1] 1 (8) [1]
Pruritus 1 (17) [1]
Values are expressed as number of subjects (%) [number of AEs]
AE adverse event
a Includes 6 subjects from Study 1A, 12 subjects from Study 1B (these subjects were counted twice) and 11 subjects from Study 1C
b Combination of period treatment with Plumpy’Nut (N = 12) and with rice and beans (N = 11). The subjects were considered as different
populations
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of at least 10,000 ng/mL, which is consistent with potential
efficacy in the second stage of the disease. The study shows
a peak in M2 concentrations between day 4 (Cmax
18,800 ng/mL) and day 7, with elevated levels maintained
until day 10 (Cmax 12,000 ng/mL) (Table 8). Taking into
account the high free fraction of the two metabolites, these
results indicate that this drug regimen would yield M2
concentrations above required levels for efficacy, deduced
from the mice study ([10,000 ng/mL for at least 2 days
[9]), for at least 6 days (day 4 to day 10) in at least 83 % of
subjects. These data are illustrated in Fig. 4, and are
compared to the predicted concentration of the drugs from
animal models required to kill 100 % of parasites in the
central nervous system.
4 Discussion
There is a great need for a safe, effective and preferably oral
treatment for HAT. The coadministration of oral nifurtimox
with intravenous eflornithine (NECT) is much safer than the
previously used highly toxic, arsenic-based melarsoprol,
and is the current best treatment for stage 2 HAT, having
been included on the WHO Essential Medicines list since
2009. However, NECT still requires hospitalisation during
the administration of the slow twice-daily infusions of
eflornithine over a period of 7 days together with thrice-
daily administration of nifurtimox for 10 days.
Nitroimidazoles have long been used for the treatment
of parasitic diseases: metronidazole, the first class of
Table 3 Number (%) of subjects experiencing study drug-related adverse events and number of adverse events after multiple oral doses of
fexinidazole (Studies 1C and 3)
AE Study 1C (fasted) Study 3 (fed)
1,200 mg od 2,400 mg od 3,600 mg od 1,800 mg od for 4 days ?
1,200 mg od for 6 days
2,400 mg od for 4 days ?
1,200 mg od for 6 days
Number of subjects exposed 7 7 7 18 4
Headache 2 (29) [2] 6 (86) [11] 3 (43) [4] 12 (67) [23] 3 (75) [4]
Vomiting 3 (43) [5] 1 (14) [1] 9 (50) [12] 2 (50) [11]
Nausea 1 (14) [1] 1 (14) [1] 9 (50) [9] 4 (100) [6]
Diarrhoea 1 (14) [1] 1 (14) [1] 3 (17) [4]
Gastro-oesophageal reflux disease 4 (22) [4] 1 (25) [1]
Abdominal pain 1 (6) [1]
Dizziness 2 (11) [2]
Dizziness postural 2 (50) [3]
Hot flush 3 (17) [3]
Abdominal pain upper 1 (14) [1] 1 (25) [1]
Anxiety 1 (25) [1]
Dyspepsia 1 (14) [2]
Panic attack 2 (50) [2]
Sleep disorder 1 (25) [1]
Asthenia 1 (6) [1]
Chest pain 1 (6) [1]
Dysuria 1 (14) [1]
Fatigue 1 (6) [1]
Hyperhidrosis 1 (6) [1]
Insomnia 1 (25) [1]
Keratitis 1 (14) [1]
Myalgia 1 (14) [1]
Palpitations 1 (14) [1]
Paraesthesia 1 (14) [1]
Pyrexia 1 (14) [1]
Regurgitation 1 (6) [1]
Somnolence 1 (14) [1]
Transaminases increased 1 (14) [1]
Values are expressed as number of subjects (%) [number of AEs]
AE adverse event, od once daily
Determination of an Optimal Dosing Regimen for Fexinidazole 573
nitroimidazoles, was discovered in the mid 1950s at
Rhoˆne-Poulenc during the search for a cure for the sexually
transmitted disease trichomoniasis. Since then, derivatives
have been used for the treatment of a number of bacterial
and protozoan diseases. Fexinidazole was identified by
DNDi out of hundreds of nitroimidazole compounds as a
promising anti-protozoal drug candidate for the treatment
of sleeping sickness.
Table 4 Plasma pharmacokinetic parameters of fexinidazole (single-dose studies)
Study Dose (mg) n tmax (h) Cmax (ng/mL) AUClast (ngh/mL) AUC? (ngh/mL) tb (h)
SAD (solution) 100 6 3 (0.5–4) 130 (23) 1,264 (32) 1,287 (32) 9 (43)
200 6 3 (1–4) 139 (44) 1,368 (56) 1,384 (56) 12 (58)
400 6 3.5 (2–6) 171 (39) 2,059 (39) 2,075 (39) 15 (54)
800 6 4 (2–6) 532 (31) 7,206 (23) 7,387 (22) 13 (47)
1,200 6 4 (3–6) 479 (77) 5,282 (56) 5,492 (52) 9 (29)
1,800 6 4 (1–4) 483 (54) 5,650 (56) 6,094 (54) 10 (20)
2,400 6 4 (3–9) 671 (32) 11,464 (43) 11,634 (43) 11 (46)
3,000 6 4 (3–4) 749 (19) 12,417 (24) 12,627 (24) 13 (41)
3,600 6 3.5 (1–6) 715 (20) 14,934 (45) 15,174 (44) 13 (45)
F/FE 1,200S/F 12 3 (1–4) 559 (32) 6,671 (42) 6,861 (41) 10 (28)
1,200T/F 12 2 (1–4) 418 (38) 4,611 (50) 5,073 (47) 11 (30)
1,200T/FD 12 5 (2–6) 1,790 (29) 21,473 (15) 21,636 (14) 11 (34)
FE 1,200T/F 11 3 (1–4) 262 (55) 3,295 (49) 3,996 (40) 11 (27)
1,200T/FD1 11 3 (2–4) 1,006 (42) 9,719 (39) 9,889 (38) 11 (25)
1,200T/FD2 11 4 (2–6) 1,026 (36) 11,435 (45) 11,660 (44) 11 (38)
Values are expressed as geometric mean (% coefficient of variation), except for tmax which are median (range)
AUC area under the plasma concentration–time curve, AUClast AUC from time zero to last measurable concentration, AUC? AUC from time
zero to infinity, Cmax maximum plasma concentration, F/FE food and formulation effect, FE food effect, S/F solution fasted, T/F tablet fasted,
T/FD tablet fed (high-fat breakfast), T/FD1 tablet fed(Plumpy’Nut), T/FD2 tablet fed (rice and beans), tb terminal elimination half-life,
tmax time to reach Cmax, SAD single ascending dose
Table 5 Plasma pharmacokinetic parameters of fexinidazole sulfoxide (M1) (single-dose studies)
Study Dose (mg) n tmax (h) Cmax (ng/mL) AUClast (ngh/mL) AUC? (ngh/mL) tb (h)
SAD (solution) 100 6 2 (2–4) 1,011 (24) 11,787 (25) 12,241 (23) 8 (22)
200 6 4 (3–6) 1,239 (27) 16,639 (27) 17,007 (27) 10 (49)
400 6 4 (3–6) 1,825 (33) 23,042 (31) 23,283 (31) 9 (27)
800 6 5 (4–6) 2,698 (31) 43,763 (24) 44,117 (24) 13 (60)
1,200 6 5 (4–6) 2,355 (36) 38,729 (22) 39,009 (22) 10 (39)
1,800 6 5 (1–6) 3,269 (26) 59,264 (34) 59,574 (34) 10 (33)
2,400 6 4 (4–9) 4,105 (26) 89,521 (29) 89,892 (28) 13 (46)
3,000 6 6 (4–6) 4,014 (8) 83,515 (9) 83,880 (9) 14 (38)
3,600 6 5 (2–6) 4,746 (59) 119,284 (47) 119,897 (47) 15 (44)
F/FE 1,200S/F 12 4 (3–6) 3,067 (27) 52,751 (41) 53,080 (41) 11 (39)
1,200T/F 12 3 (2–6) 2,283 (33) 40,679 (55) 41,080 (54) 10 (34)
1,200T/FD 12 6 (4–9) 9,026 (15) 159,522 (20) 159,908 (20) 12 (36)
FE 1,200T/F 11 4 (1–6) 2,114 (45) 33,707 (50) 34,092 (49) 10 (33)
1,200T/FD1 11 4 (3–6) 5,978 (29) 81,726 (31) 82,156 (31) 12 (41)
1,200T/FD2 11 6 (2–6) 6,223 (32) 94,589 (42) 95,035 (42) 12 (39)
Values are expressed as geometric mean (% coefficient of variation), except for tmax which are median (range)
AUC area under the plasma concentration–time curve, AUClast AUC from time zero to last measurable concentration, AUC? AUC from time
zero to infinity, Cmax maximum plasma concentration, F/FE food and formulation effect, FE food effect, S/F solution fasted, T/F tablet fasted,
T/FD tablet fed (high-fat breakfast), T/FD1 tablet fed (Plumpy’Nut), T/FD2 tablet fed (rice and beans), tb terminal elimination half-life,
tmax time to reach Cmax, SAD single ascending dose
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In Study 1A, doses of fexinidazole ranging from 100 to
3,600 mg were found to be safe and well-tolerated. The
decision to stop dosing at 3,600 mg was not based on
potential safety or tolerability issues, but rather on the fact
it was considered extremely unlikely that higher doses
could be used in a clinical trial setting. The tolerability
issue affecting transaminase levels observed following
multiple dosing with the 3,600 mg/day oral tablet in one
Table 6 Plasma pharmacokinetic parameters of fexinidazole sulfone (M2) (single-dose studies)
Study Dose (mg) n tmax (h) Cmax (ng/mL) AUClast (ngh/mL) AUC? (ngh/mL) tb (h)
SAD (solution) 100 6 18 (12–24) 656 (21) 31,909 (22) 32,349 (23) 19 (15)
200 6 24 (16–24) 916 (28) 43,722 (27) 47,239 (27) 21 (15)
400 6 14 (12–24) 1,286 (31) 60,901 (37) 61,375 (37) 20 (11)
800 6 24 (16–24) 2,231 (39) 119,938 (32) 121,050 (31) 21 (24)
1,200 6 24 (12–24) 2,236 (43) 110,986 (38) 111,507 (38) 18 (5)
1,800 6 24 (16–24) 3,085 (34) 162,410 (35) 163,142 (35) 18 (13)
2,400 6 24 (16–24) 3,518 (31) 217,366 (36) 219,275 (37) 20 (17)
3,000 6 24 (24–24) 3,985 (20) 223,299 (14) 225,030 (14) 20 (16)
3,600 6 24 (24–48) 5,864 (55) 418,476 (51) 427,770 (50) 25 (18)
F/FE 1,200S/F 12 24 (12–48) 2,709 (25) 151,372 (31) 152,499 (32) 20 (18)
1,200T/F 12 24 (16–24) 1,980 (37) 107,466 (45) 108,094 (45) 19 (15)
1,200T/FD 12 24 (16–24) 7,915 (22) 458,091 (14) 462,234 (14) 21 (13)
FE 1,200T/F 11 24 (12–24) 1,854 (46) 101,385 (53) 102,533 (53) 19 (17)
1,200T/FD1 11 16 (9–24) 4,483 (43) 261,658 (43) 263,832 (43) 21 (13)
1,200T/FD2 11 24 (12–24) 5,333 (39) 297,796 (39) 300,263 (39) 20 (21)
Values are expressed as geometric mean (% coefficient of variation), except for tmax which are median (range)
AUC area under the plasma concentration–time curve, AUClast AUC from time zero to last measurable concentration, AUC? AUC from time
zero to infinity, Cmax maximum plasma concentration, F/FE food and formulation effect, FE food effect, S/F solution fasted, T/F tablet fasted,
T/FD tablet fed (high-fat breakfast), T/FD1 tablet fed (Plumpy’Nut), T/FD2 tablet fed (rice and beans), tb terminal elimination half-life,
tmax time to reach Cmax, SAD single ascending dose
Table 7 Plasma pharmacokinetic parameters of fexinidazole and metabolites (M1, M2) (multiple ascending dose studies, tablet under fasted
condition)
Parameter 1,200 mg (n = 6) 2,400 mg (n = 6) 3,600 mg (n = 6)
Day 1 Day 7 Day 14 Day 1 Day 7 Day 14 Day 1 Day 7 Day 14
Fexinidazole
tmax (h) 3 (3–4) 4 (3–4) 3 (3–12) 3.5 (1–4) 4 (3–6) 3 (0–6) 3 (0.5–4) 4 (3–4) 4 (3–4)
Cmax (ng/mL) 265 (45) 303 (50) 385 (39) 512 (34) 516 (16) 486 (24) 453 (29) 653 (19) 635 (12)
AUC24 (ngh/mL) 2,444 (48) 3,718 (49) 4,773 (54) 5,335 (39) 7,085 (24) 7,605 (23) 5,605 (18) 9,625 (18) 9,301 (16)
M1
tmax (h) 4 (2–4) 4 (2–6) 3.5 (3–4) 3 (2–6) 4 (3–6) 3 (3–4) 3 (2–4) 4 (4–4) 4 (3–6)
Cmax (ng/mL) 2,020 (21) 2,892 (14) 4,469 (29) 3,097 (27) 5,385 (23) 5,603 (32) 3,216 (17) 7,237 (19) 7,912 (15)
AUC24
(ngh/mL)
25,246 (27) 43,113 (37) 66,811 (34) 41,997 (31) 82,908 (23) 87,096 (28) 47,742 (9) 124,547 (21) 129,270 (18)
M2
tmax (h) 24 (16–24) 4 (0.5–9) 5.5 (0–24) 24 (16–24) 2.5 (1–12) 9 (0–48) 24 (24–24) 16 (0–24) 2 (0–24)
Cmax (ng/mL) 1,827 (36) 7,375 (29) 10,957 (43) 2,697 (32) 14,678 (31) 14,758 (33) 3,405 (9) 21,257 (8) 24,429 (16)
AUC24
(ngh/mL)
29,858 (37) 153,130 (31) 235,400 (39) 41,973 (27) 307,563 (27) 302,746 (31) 50,030 (8) 465,415 (8) 512,221 (14)
Values are expressed as geometric mean (% coefficient of variation), except for tmax which are median (range)
AUC24 area under the plasma concentration–time curve from time zero to 24 h, Cmax maximum plasma concentration, tmax time to reach Cmax
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single subject at day 15 (Study 1C) further supported this
decision. After oral administration, fexinidazole was
absorbed and metabolised rapidly via a wide range of
cytochrome P450 (CYP) enzymes and via the human fla-
vine mono-oxygenase-3 (FMO-3) enzyme, observed
in vitro (unpublished data on file), indicating a low risk of
adverse drug interactions—the wide range of possible
metabolic pathways via CYP indicates a low adverse drug
reaction risk (drug–drug interaction) as alternative meta-
bolic pathways exist if there is any drug–drug competition
for a particular metabolic pathway.
The first metabolite, M1, appeared rapidly in plasma.
The M2 metabolite peaked around 24 h after fexinidazole
administration, with a mean terminal t of about 24 h. As a
result of these contrasting t values, once-daily adminis-
tration did not lead to marked accumulation of fexinidazole
and M1, whilst the accumulation ratio for M2 was about 7.
In these human studies, the free fraction of fexinidazole
and its metabolites was 2 % for fexinidazole and about 60
and 43 % for M1 and M2, respectively, matching the
available in vitro data [10]. The pattern of absorption,
metabolism and elimination is qualitatively similar to that
seen in animal studies [9]. After oral administration of
ascending single doses between 0.75 and 3.15 % of the
fexinidazole dose was recovered unchanged or as M1 or
M2 in urine over 168 h. This indicates that the elimination
route of fexinidazole is almost entirely extra-renal. This
conclusion is supported by the renal clearance rate, which
is low (mean values around about 1.2–6.0 mL/h, Study 1A)
when compared with the apparent oral clearance (mean
CL/F of more than 80 L/h for all three compounds).
Data from Study 1B indicate that the tablet form is
absorbed approximately 25 % less efficiently than the
suspension form. It is likely that this reduction in overall
absorption of fexinidazole in the tablet form reflects the
time taken for full disintegration and dissolution of the
tablets relative to the rate of gastric emptying. Fexinidazole
can be considered to be a Biopharmaceutical Classification
System (BCS) Class III drug [19] in terms of its solubility
and absorption properties, such that the rate of drug dis-
solution is likely to be the determining factor for the degree
of absorption within a given gastric transit period.
The effect of concomitant food intake on fexinidazole
bioavailability was unexpected given the preclinical data or
existing literature on the drug class [21, 23]. There is
evidence that metronidazole absorption is retarded if taken
with food [22], and whilst it is recommended that the
clinically available 5-nitroimidazole drugs be taken with
food to reduce the risk of gastrointestinal adverse effects,
no change in oral bioavailability has been described [24].
These data, coupled with the results from Study 2 indi-
cating that the type of food taken does not influence the
bioavailability, support the notion that the observed bio-




(M1, M2) (multiple-dose studies
under fed condition)
Values are expressed as
geometric mean (% coefficient
of variation), except for tmax
which are median (range)
AUC24 area under the plasma
concentration–time curve from
time zero to 24 h, Cmax
maximum plasma
concentration, tmax time to reach
Cmax
Parameter (N = 12) 1,800 mg 1,800 mg 1,200 mg
Day 1 Day 4 Day 7 Day 10
Fexinidazole
tmax (h) 4 (2–9) 4 (0–9) 4 (0–6) 4 (2–9)
Cmax (ng/mL) 1,519 (24) 777 (35) 336 (50) 486 (40)
AUC24 (ngh/mL) 14,105 (18) 11,410 (19) 6,285 (18) 6,596 (36)
M1
tmax (h) 4 (3–6) 4 (0–6) 4 (0–6) 3.5 (2–6)
Cmax (ng/mL) 7,818 (27) 7,768 (29) 3,999 (43) 5,574 (36)
AUC24 (ngh/mL) 98,511 (28) 119,963 (38) 52,501 (47) 77,263 (43)
M2
tmax (h) 23 (16–23.5) 6 (0–23.5) 3 (0–12) 4 (0–24)
Cmax (ng/mL) 6,837 (44) 18,790 (28) 13,520 (36) 12,060 (28)
AUC24 (ngh/mL) 103,089 (37) 370,415 (32) 250,411 (36) 242,756 (29)
Fig. 1 Arithmetic mean plasma concentrations of fexinidazole,
fexinidazole sulfoxide (M1) and fexinidazole sulfone (M2) after a
single oral dose of fexinidazole 3,600 mg suspension (data from
Study 1A)
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rather than to an effect on gastrointestinal tract physiology.
Overall, it is possible that an increase in time available for
gastric absorption may allow for a prolonged residence
time for fexinidazole at the site of intestinal absorption,
Fig. 2 Dose proportionality of increasing doses of fexinidazole oral
suspension following increasing doses of fexinidazole suspension and
fexinidazole sulfone (M2) assessed from the single ascending dose
study (Study 1A): a Cmax, b AUC0–?. Cmax maximum plasma
concentration, AUC0–? area under the plasma concentration–time
curve from time zero to infinity
Fig. 3 Arithmetic mean plasma concentrations of fexinidazole sul-
fone (M2) after single oral dose of fexinidazole 1,200 mg tablets
given with or without food (high-fat breakfast, Plumpy’Nut, and rice
and beans meals) (data from Study 1B and 2)
Fig. 4 Geometric means of the maximum plasma concentration
(n = 12) for fexinidazole, fexinidazole sulfoxide (M1) and fexini-
dazole sulfone (M2) at days 1, 4, 7 and 10 after oral dosing with
fexinidazole tablets as per cohort 1 in Study 3. Cmax maximum
plasma concentration, IC90 concentration needed to inhibit 90 %
parasite growth
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thus increasing initial metabolism in the gastric intestinal
mucosa, providing for higher overall levels of M1, and
subsequently M2, in the systemic circulation, as has been
proposed for some cephalosporin pro-drugs [25]. The
minimal changes in metabolic ratios after food also suggest
that the increased bioavailability is not due to changes in
the rate of biotransformation of fexinidazole to M1 or of
M1 to M2. A decrease in gastric pH may also contribute to
an improved disintegration and dissolution profile for
fexinidazole tablets and thus an increased absorption
potential; however, it is not known whether such a decrease
occurred in the current studies.
In Study 1C, clinically significant changes in safety
laboratory tests were observed after the last day of dosing,
especially in the liver function test (LFT). In one subject,
LFT plasma levels rapidly increased before rapidly
decreasing the next day. On further expert analysis, it was
concluded that the results did not follow Hay’s law
(hepatocellular injury sufficient to cause hyperbilirubina-
emia acts as an indicator of the potential for a drug to cause
serious liver injury) [26, 27] and thus could be considered
as an isolated reaction to the study drug. The variations in
creatinine seen in Study 1C were considered likely to have
been caused via inhibition of renal tubular secretion of
creatinine, as reported for the drug class [19], and it is also
likely that the smaller increases in transaminases noted
were due to the conditions of the study, as such rises have
been seen in many first-in-man trials [28].
The increase in absorption of the drug when taken with
food clearly provides an opportunity for maximising sys-
temic drug concentrations. Typically, the carbohydrate
staple of the main meal in endemic areas is ‘fufu’, a solid
paste of manioc with or without maize, or sometimes just
rice. Chicken or fish cooked in palm oil are a source of
protein. The food type comparison data from Study 2
showed that a normal meal, likely to be readily available to
HAT patients, was sufficient to obtain 2.5–3 times higher
plasma concentrations, particularly of M2, when compared
with fasted condition. Therefore, a population pharmaco-
kinetic model was developed [29] in order to find a treat-
ment schedule that allowed high plasma M2 ([10,000 ng/
mL,) levels to be reached on day 2–3 (compared with day 4
under fasted conditions) and maintained for at least 4 days.
These simulated results were tested in healthy volunteers to
ensure that such an increase does not introduce unaccept-
able adverse effects. The aim of this last study (Study 3)
was to select the best treatment regimen to be used for a
phase II/III trial.
Study 3 shows the best tolerated treatment regimen to be
1,800 mg once a day for 4 days followed by 1,200 mg
once a day for 6 days after the main meal of the day. The
tolerability was considered to be acceptable, and although
some headache and nausea AEs occurred initially, they
were only of mild to moderate severity and spontaneously
reverted during treatment. Safety laboratory tests con-
ducted during the study did not detect any of the abnor-
malities seen in the 14-day dosing regimen used in
Study 1C. This improved tolerability, particularly in rela-
tion to the concerns around the LFTs, supported the
hypothesis that a possible accumulation of high-dose drug
product rather than any specific product sensitivity of the
liver were the most likely causes of the LFT abnormalities
seen during the 14-day multiple-dose study.
Electrocardiograms were recorded during all studies and
were specifically analysed by an independent cardiologist
for variations in QT/QTc intervals. No out-of-range values
of the QTc in all the ECGs were detected. However,
compared with placebo and baseline, an average, non-dose-
dependent variation was elicited in QT/QTc of around
16 ms.
5 Conclusions
First-in-man clinical studies have demonstrated that doses
of up to 3,600 mg of fexinidazole in fasted conditions are
safe and well-tolerated in healthy male subjects of sub-
Saharan origin. The main reported AEs were headache and
vomiting of acceptable intensity, which spontaneously
resolved in all cases. A dosing regimen of fexinidazole
1,800 mg for 4 days and 1,200 mg for 6 days with con-
comitant food was shown to meet the required criteria of
effective drug concentrations with a good safety profile.
Based on the available in vitro and animal model data, it
can be predicted that the proposed dosing regimen would
be effective in curing both stage 2 and stage 1 HAT. This
prediction is currently being tested in a pivotal phase II/III
comparative study in stage 2 patients in HAT endemic
regions and, if successful, will provide patients with the
first oral treatment for stage 2 sleeping sickness, which
could revolutionise treatment in the field.
The oxaborole SCYX-7158 has recently entered
phase I clinical studies for the treatment of sleeping
sickness. As far as we are aware, fexinidazole is the only
new drug currently in phase II/III clinical development
for the treatment of stage 2 sleeping sickness. Moreover,
it has recently been shown to be active against visceral
leishmaniasis and Chagas disease [12, 30]. These find-
ings illustrate the potential of fexinidazole as a drug
candidate for the treatment of different kinetoplastid
diseases.
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